Complete Response Letter

Last updated

In United States pharmaceutical regulatory practice, a Complete Response Letter (CRL), or more rarely, a 314.110 letter, is a regulatory action by the Food and Drug Administration in response to a New Drug Application, Amended New Drug Application or Biologics License Application, indicating that the application will not be approved in its present form. [1] CRLs replaced approvable letters in 2018.

Contents

Background

Under the Prescription Drug User Fee Act, the Food and Drug Administration has a limited timespan (known as the PDUFA date) to decide a New Drug Application, Abbreviated New Drug Application or Biologics License Application. The FDA may either approve the application or issue a Complete Response Letter. [2] Grounds behind issuing a CRL may include labeling issues, current Good Manufacturing Practice concerns or concerns about the safety or effectiveness of the drug. [3]

A sponsor receiving CRL may withdraw the application, request a hearing or resubmit the application. [1] Because hearings are open to the public, this course of action is relatively rarely chosen. [4]

Class 1 and Class 2 resubmissions after CRLs

MAPP 6020 Rev. 2, the Food and Drug Administration policy manual governing resubmissions following a CRL, classifies CRLs as requiring a Class 1 or Class 2 resubmission. [5] Where a sponsor decides to submit a response to a CRL, the response is classified within 30 days, if the response is complete. [6] A Class 1 response typically denotes minor amendments, such as labeling, assay validation data or minor re-analysis of the data supporting the application, while a Class 2 response typically involves more extensive concerns and/or a reinspection. [6] A Class 1 response is typically handled within 3 months, while a Class 2 response is typically handled within 6 months. [5]

Economic impact

A CRL frequently has a significant impact on the sponsor's share price. Orphazyme, a Danish biopharmaceutical company, lost over half of its share value overnight upon disclosing a CRL for arimoclomol, a proposed treatment for Niemann–Pick disease, type C, [7] forcing the company to restructure. [8] BioMarin Pharmaceutical lost over 30% of its value when a CRL was issued in respect of its hemophilia A gene therapy, valoctocogene roxaparvovec. [9] Sesen Bio's stock price dropped over 80% after reporting a CRL for Vicineum as a treatment for a type of bladder cancer. [10]

Disclosure

Typically, CRLs are not disclosed publicly as they often include proprietary information. [11] Press releases, when issued, typically do not include most of the details contained in the CRL, including the reasons behind it. [12] While there is no general obligation to publicly disclose a CRL's existence or contents, the U.S. Securities and Exchange Commission has in the past brought action against companies that allegedly misled investors about a CRL. [13]

Related Research Articles

<span class="mw-page-title-main">Food and Drug Administration</span> United States federal agency

The United States Food and Drug Administration is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, caffeine products, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), cosmetics, animal foods & feed and veterinary products.

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

<span class="mw-page-title-main">Adrafinil</span> Wakefulness-promoting drug

Adrafinil, sold under the brand name Olmifon, is a wakefulness-promoting medication that was formerly used in France to improve alertness, attention, wakefulness, and mood, particularly in the elderly. It was also used off-label by individuals who wished to avoid fatigue, such as night workers or others who needed to stay awake and alert for long periods of time. Additionally, the medication has been used non-medically as a novel vigilance-promoting agent.

<span class="mw-page-title-main">New Drug Application</span> Request US FDA approve new medications

The Food and Drug Administration's (FDA) New Drug Application (NDA) is the vehicle in the United States through which drug sponsors formally propose that the FDA approve a new pharmaceutical for sale and marketing. Some 30% or less of initial drug candidates proceed through the entire multi-year process of drug development, concluding with an approved NDA, if successful.

<span class="mw-page-title-main">Flibanserin</span> Medication

Flibanserin, sold under the brand name Addyi, is a medication approved for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). The medication improves sexual desire, increases the number of satisfying sexual events, and decreases the distress associated with low sexual desire. The most common side effects are dizziness, sleepiness, nausea, difficulty falling asleep or staying asleep and dry mouth.

<span class="mw-page-title-main">Prescription Drug User Fee Act</span> Legislation in the United States

The Prescription Drug User Fee Act (PDUFA) was a law passed by the United States Congress in 1992 which allowed the Food and Drug Administration (FDA) to collect fees from drug manufacturers to fund the new drug approval process. The Act provided that the FDA was entitled to collect a substantial application fee from drug manufacturers at the time a New Drug Application (NDA) or Biologics License Application (BLA) was submitted, with those funds designated for use only in Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) drug approval activities. In order to continue collecting such fees, the FDA is required to meet certain performance benchmarks, primarily related to the speed of certain activities within the NDA review process.

<span class="mw-page-title-main">Iloperidone</span> Atypical antipsychotic medication

Iloperidone, commonly known as Fanapt and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia.

Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease. The priority review voucher program is a program that grants a voucher for priority review to a drug developer as an incentive to develop treatments for disease indications with limited profitability.

Spectrum Pharmaceuticals, Inc. is an American biopharmaceutical company located in Boston, MA. It develops and markets drugs for treatments in hematology and oncology.

<span class="mw-page-title-main">Phentermine/topiramate</span> Obesity medication

Phentermine/topiramate, sold under the brand name Qsymia, is a combination drug of phentermine and topiramate used to treat obesity. It is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped. The weight loss is modest. Effects on heart related health problems or death is unclear.

Melior Discovery, Inc. is a private biopharmaceutical company based in Exton, Pennsylvania, USA.

An FDA warning letter is an official message from the United States Food and Drug Administration (FDA) to a manufacturer or other organization that has violated some rule in a federally regulated activity.

<span class="mw-page-title-main">Lasmiditan</span> Chemical compound

Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute treatment of migraine with or without aura in adults. It is not useful for prevention. It is taken by mouth.

<span class="mw-page-title-main">Food and Drug Administration Safety and Innovation Act</span> Piece of American regulatory legislation

The Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA) is a piece of American regulatory legislation signed into law on July 9, 2012. It gives the United States Food and Drug Administration (FDA) the authority to collect user fees from the medical industry to fund reviews of innovator drugs, medical devices, generic drugs and biosimilar biologics. It also creates the breakthrough therapy designation program and extends the priority review voucher program to make eligible rare pediatric diseases. The measure was passed by 96 senators voting for and one voting against.

<span class="mw-page-title-main">Efinaconazole</span> Chemical compound

Efinaconazole, sold under the brand name Jublia among others, is a triazole antifungal medication. It is approved for use in the United States, Canada, and Japan as a 10% topical solution for the treatment of onychomycosis. Efinaconazole acts as a 14α-demethylase inhibitor.

<span class="mw-page-title-main">Zuranolone</span> Medication used for postpartum depression

Zuranolone, sold under the brand name Zurzuvae, is a medication used for the treatment of postpartum depression. It is taken by mouth.

Approvable letters, and the related non-approvable letters, were notifications sent out by the Food and Drug Administration (FDA) to drug manufacturers alerting them to the approval prospects of their drugs under development. The letters were intended to let manufacturers know how much work is needed on their applications. Non-approval letters were rejections of a drug's application. Approvable and non-approvable letters were covered under Title 21 of the Code of Federal Regulations, section 314.110.

RVT-802 is a medication being developed by Enzyvant Therapeutics Ireland Limited for the treatment of congenital athymia, especially in the context of DiGeorge syndrome.

In United States pharmaceutical regulatory practice, the PDUFA date is the colloquial name for the date by which the Food and Drug Administration must respond to a New Drug Application or a Biologics License Application. It is part of the regime established by the Prescription Drug User Fee Act to ensure funding of the Food and Drug Administration's drug approval activities in return for adhering to a largely fixed timetable of regulatory actions.

Valoctocogene roxaparvovec, sold under the brand name Roctavian, is a gene therapy used for the treatment of hemophilia A. It was developed by BioMarin Pharmaceutical. Valoctocogene roxaparvovec is made of a virus (AAV5) that has been modified to contain the gene for factor VIII, which is lacking in people with hemophilia A. It is an adeno-associated virus vector-based gene therapy. It is given by intravenous infusion.

References

  1. 1 2 "21 CFR 314.110". www.accessdata.fda.gov. Retrieved 2021-06-30.
  2. ↑ Thayer, Ann M. (15 May 2017). "The complete response letter: The mail no one wants to receive". ACS C&EN. Retrieved 2021-06-30.
  3. ↑ Chandanais, Ryan (8 December 2017). "Complete Response Letters: What Drug Manufacturers Hope to Avoid". Pharmacy Times. Retrieved 2021-06-30.
  4. ↑ "FDA Complete Response Letters: The design v. reality of FDA's responses to drug applications". Healthcare Law Insights. 2015-01-12. Retrieved 2021-06-30.
  5. 1 2 "MAPP 6020.5 Rev. 2: Classifying Resubmissions of original NDAs, BLAs and Efficacy Cupplements in Response to Complete Response Letters". Food and Drug Administration, Center for Drug Evaluation and Research. Retrieved 2021-06-30.
  6. 1 2 "MAPPing Out The Timing Of A Complete Response Submission". Camargo. 27 February 2015. Retrieved 2021-06-30.
  7. ↑ Kilgore, Tomi. "Orphazyme stock plunges after receiving CRL from FDA after review of NPC treatment". MarketWatch. Retrieved 2021-06-30.
  8. ↑ ORPHAZYME A/S (2021-06-28). "Orphazyme announces restructuring to focus resources on supporting a path forward for arimoclomol in NPC". GlobeNewswire News Room. Retrieved 2021-06-30.
  9. ↑ Fox, Matthew (19 August 2020). "2 biotech stocks plummet more than 25% after the FDA rejects their drug applications". Business Insider . Retrieved 2021-06-30.
  10. ↑ "FDA rejects Sesen Bio's bladder cancer pitch, sending shares spiraling back to penny stock territory". Endpoints News. Retrieved 2021-08-16.
  11. ↑ Mullard, Asher (2015-07-01). "Should the FDA disclose complete response letters?". Nature Reviews Drug Discovery. 14 (7): 449. doi: 10.1038/nrd4686 . ISSN   1474-1784. S2CID   34872830.
  12. ↑ Lurie, Peter; Chahal, Harinder S.; Sigelman, Daniel W.; Stacy, Sylvie; Sclar, Joshua; Ddamulira, Barbara (2015-06-10). "Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study". BMJ. 350: h2758. doi:10.1136/bmj.h2758. ISSN   1756-1833. PMC   4462714 . PMID   26063327.
  13. ↑ "SEC.gov | FCPA, Disclosure, and Internal Controls Issues Arising in the Pharmaceutical Industry". www.sec.gov. Retrieved 2021-06-30.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.